Alkermes, Inc.

Alkermes Pharma Ireland Limited

Mural Oncology, Inc.

Heather C Losey

Jared Lopes

Raymond J Winquist

Juan C Alvarez

Demetri Theodore Moustakas

Mark N Namchuk

Jean Chamoun

Lei Sun

Juan Alvarez

The invention provides compositions, methods and treatment regimens for treating cancer comprising periodic subcutaneous administration of the fusion protein of SEQ ID NO:1 to a cancer patient resulting in enhanced activation of CD8+ T-cells with minimal effects on regulatory T cell (T) expansion and providing enhanced anti-tumor efficacy while also mitigating T cell inactivation/exhaustion.

Compositions and methods for subcutaneous administration of cancer immunotherapy

The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising a fusion protein of SEQ ID NO: 1 in combination with an immune checkpoint inhibitor. Preferably the patient has failed to achieve complete or partial response with prior or ongoing treatment with an immune checkpoint inhibitor.

Immunomodulatory IL-2 agents in combination with immune checkpoint inhibitors

The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).

Immunostimulatory agents in combination with angiogenesis inhibitors

The invention provides compositions and methods for modulating the immunostimulatory properties and/or anti-inflammatory properties of IL-10. The present invention provides scIL-10 polypeptides of Formula 1. The polypeptides of the invention are optionally linked to a fusion partner. The polypeptides of Formula 1 are referred to herein as 'scIL-10' polypeptides and comprise an amino acid sequence arrangement from N-terminus to C-terminus in accordance with Formula 1:(first monomer subunit)-LINKER-(second monomer subunit)&#x2003;&#x2003; Formula 1wherein the first monomer subunit, the second monomer subunit or both the first and second monomer subunits may be independently selected from: an unsubstituted IL-10 monomer subunit; or a substituted IL-10 monomer subunit comprising at least one amino acid substitution; and wherein LINKER is any amino acid linker of at least 1-100 amino acids in length.

Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties

The invention provides compositions and methods for modulating the immunostimulatory properties and/or anti-inflammatory properties of IL-10. The present invention provides scIL-10 polypeptides of Formula 1. The polypeptides of the invention are optionally linked to a fusion partner. The polypeptides of Formula 1 are referred to herein as 'scIL-10' polypeptides and comprise an amino acid sequence arrangement from N-terminus to C-terminus in accordance with Formula 1:(first monomer subunit)-LINKER-(second monomer subunit)&#x2003;&#x2003; Formula 1

Compositions for modulating IL-10 immunostimulatory and anti-inflammatory properties

The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention.

Growing community of inventors

Lexington, MA, United States of America

Heather C Losey